FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2395071949> ?p ?o ?g. }

• W2395071949 endingPage "652" @default.
• W2395071949 startingPage "646" @default.
• W2395071949 abstract "Background The use of non-invasive ventilation is controversial in immunocompromised patients with acute respiratory failure, whereas the use of high-flow nasal cannula oxygen therapy is growing as an alternative to standard oxygen. We aimed to compare outcomes of immunocompromised patients with acute respiratory failure treated with standard oxygen with those treated with high-flow nasal cannula oxygen alone or high-flow nasal cannula oxygen associated with non-invasive ventilation. Methods We did a post-hoc subgroup analysis in a subset of immunocompromised patients with non-hypercapnic acute respiratory failure from a multicentre, randomised, controlled trial. In the trial, patients from 23 intensive care units in France and Belgium were randomly assigned (1:1:1) to receive either standard oxygen, high-flow nasal cannula alone, or non-invasive ventilation interspaced with high-flow nasal cannula between non-invasive ventilation sessions (non-invasive ventilation group). Patients with profound neutropenia, acute-on-chronic respiratory failure, cardiogenic pulmonary oedema, shock, or altered consciousness were excluded. The primary outcome was the proportion of patients who required endotracheal intubation within 28 days after randomisation. Findings Of the 82 immunocompromised patients, 30 were treated with standard oxygen, 26 with high-flow nasal cannula alone, and 26 with non-invasive ventilation plus interspaced high-flow nasal cannula. 8 (31%) of 26 patients treated with high-flow nasal cannula alone, 13 (43%) of 30 patients treated with standard oxygen, and 17 (65%) of 26 patients treated with non-invasive ventilation required intubation at 28 days (p=0·04). Odds ratios (ORs) for intubation were higher in patients treated with non-invasive ventilation than in those treated with high-flow nasal cannula: OR 4·25 (95% CI 1·33–13·56). ORs were not significantly different between patients treated with high-flow nasal cannula alone and standard oxygen: OR 1·72 (0·57–5·18). After multivariable logistic regression, the two factors independently associated with endotracheal intubation and mortality were age and use of non-invasive ventilation as first-line therapy. Interpretation Non-invasive ventilation might be associated with an increased risk of intubation and mortality and should be used cautiously in immunocompromised patients with acute hypoxaemic respiratory failure. Funding French Ministry of Health, the French societies of intensive care (Société de Réanimation de Langue Française, SRLF) and pneumology (Société de Pneumologie de Langue Française, SPLF), La Mutuelle de Poitiers, AADAIRC (Association pour l'Assistance à Domicile Aux Insuffisants Respiratoires Chroniques), and Fisher&Paykel Healthcare. The use of non-invasive ventilation is controversial in immunocompromised patients with acute respiratory failure, whereas the use of high-flow nasal cannula oxygen therapy is growing as an alternative to standard oxygen. We aimed to compare outcomes of immunocompromised patients with acute respiratory failure treated with standard oxygen with those treated with high-flow nasal cannula oxygen alone or high-flow nasal cannula oxygen associated with non-invasive ventilation. We did a post-hoc subgroup analysis in a subset of immunocompromised patients with non-hypercapnic acute respiratory failure from a multicentre, randomised, controlled trial. In the trial, patients from 23 intensive care units in France and Belgium were randomly assigned (1:1:1) to receive either standard oxygen, high-flow nasal cannula alone, or non-invasive ventilation interspaced with high-flow nasal cannula between non-invasive ventilation sessions (non-invasive ventilation group). Patients with profound neutropenia, acute-on-chronic respiratory failure, cardiogenic pulmonary oedema, shock, or altered consciousness were excluded. The primary outcome was the proportion of patients who required endotracheal intubation within 28 days after randomisation. Of the 82 immunocompromised patients, 30 were treated with standard oxygen, 26 with high-flow nasal cannula alone, and 26 with non-invasive ventilation plus interspaced high-flow nasal cannula. 8 (31%) of 26 patients treated with high-flow nasal cannula alone, 13 (43%) of 30 patients treated with standard oxygen, and 17 (65%) of 26 patients treated with non-invasive ventilation required intubation at 28 days (p=0·04). Odds ratios (ORs) for intubation were higher in patients treated with non-invasive ventilation than in those treated with high-flow nasal cannula: OR 4·25 (95% CI 1·33–13·56). ORs were not significantly different between patients treated with high-flow nasal cannula alone and standard oxygen: OR 1·72 (0·57–5·18). After multivariable logistic regression, the two factors independently associated with endotracheal intubation and mortality were age and use of non-invasive ventilation as first-line therapy. Non-invasive ventilation might be associated with an increased risk of intubation and mortality and should be used cautiously in immunocompromised patients with acute hypoxaemic respiratory failure." @default.
• W2395071949 created "2016-06-24" @default.
• W2395071949 creator A5000822953 @default.
• W2395071949 creator A5020488720 @default.
• W2395071949 creator A5022425277 @default.
• W2395071949 creator A5024199696 @default.
• W2395071949 creator A5028663302 @default.
• W2395071949 creator A5038865044 @default.
• W2395071949 creator A5055178861 @default.
• W2395071949 creator A5061797031 @default.
• W2395071949 creator A5062014879 @default.
• W2395071949 creator A5062306514 @default.
• W2395071949 creator A5066342411 @default.
• W2395071949 creator A5070071339 @default.
• W2395071949 creator A5087103452 @default.
• W2395071949 date "2016-08-01" @default.
• W2395071949 modified "2023-10-09" @default.
• W2395071949 title "Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: a post-hoc analysis of a randomised trial" @default.
• W2395071949 cites W1922120322 @default.
• W2395071949 cites W1969930920 @default.
• W2395071949 cites W1970220060 @default.
• W2395071949 cites W1979112585 @default.
• W2395071949 cites W1979312957 @default.
• W2395071949 cites W2051155516 @default.
• W2395071949 cites W2052041089 @default.
• W2395071949 cites W2069378897 @default.
• W2395071949 cites W2102852047 @default.
• W2395071949 cites W2125766343 @default.
• W2395071949 cites W2148218430 @default.
• W2395071949 cites W2149797442 @default.
• W2395071949 cites W2155110766 @default.
• W2395071949 cites W2167917082 @default.
• W2395071949 cites W2186429309 @default.
• W2395071949 cites W2194890348 @default.
• W2395071949 cites W2271264780 @default.
• W2395071949 cites W2331066743 @default.
• W2395071949 cites W4211224738 @default.
• W2395071949 cites W4236073362 @default.
• W2395071949 cites W4376453297 @default.
• W2395071949 doi "https://doi.org/10.1016/s2213-2600(16)30093-5" @default.
• W2395071949 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27245914" @default.
• W2395071949 hasPublicationYear "2016" @default.
• W2395071949 type Work @default.
• W2395071949 sameAs 2395071949 @default.
• W2395071949 citedByCount "172" @default.
• W2395071949 countsByYear W23950719492016 @default.
• W2395071949 countsByYear W23950719492017 @default.
• W2395071949 countsByYear W23950719492018 @default.
• W2395071949 countsByYear W23950719492019 @default.
• W2395071949 countsByYear W23950719492020 @default.
• W2395071949 countsByYear W23950719492021 @default.
• W2395071949 countsByYear W23950719492022 @default.
• W2395071949 countsByYear W23950719492023 @default.
• W2395071949 crossrefType "journal-article" @default.
• W2395071949 hasAuthorship W2395071949A5000822953 @default.
• W2395071949 hasAuthorship W2395071949A5020488720 @default.
• W2395071949 hasAuthorship W2395071949A5022425277 @default.
• W2395071949 hasAuthorship W2395071949A5024199696 @default.
• W2395071949 hasAuthorship W2395071949A5028663302 @default.
• W2395071949 hasAuthorship W2395071949A5038865044 @default.
• W2395071949 hasAuthorship W2395071949A5055178861 @default.
• W2395071949 hasAuthorship W2395071949A5061797031 @default.
• W2395071949 hasAuthorship W2395071949A5062014879 @default.
• W2395071949 hasAuthorship W2395071949A5062306514 @default.
• W2395071949 hasAuthorship W2395071949A5066342411 @default.
• W2395071949 hasAuthorship W2395071949A5070071339 @default.
• W2395071949 hasAuthorship W2395071949A5087103452 @default.
• W2395071949 hasConcept C126322002 @default.
• W2395071949 hasConcept C127413603 @default.
• W2395071949 hasConcept C141071460 @default.
• W2395071949 hasConcept C200457457 @default.
• W2395071949 hasConcept C2776780178 @default.
• W2395071949 hasConcept C2776888751 @default.
• W2395071949 hasConcept C2777080012 @default.
• W2395071949 hasConcept C2778074680 @default.
• W2395071949 hasConcept C2778716859 @default.
• W2395071949 hasConcept C2780334268 @default.
• W2395071949 hasConcept C2780630273 @default.
• W2395071949 hasConcept C42219234 @default.
• W2395071949 hasConcept C71924100 @default.
• W2395071949 hasConcept C78519656 @default.
• W2395071949 hasConceptScore W2395071949C126322002 @default.
• W2395071949 hasConceptScore W2395071949C127413603 @default.
• W2395071949 hasConceptScore W2395071949C141071460 @default.
• W2395071949 hasConceptScore W2395071949C200457457 @default.
• W2395071949 hasConceptScore W2395071949C2776780178 @default.
• W2395071949 hasConceptScore W2395071949C2776888751 @default.
• W2395071949 hasConceptScore W2395071949C2777080012 @default.
• W2395071949 hasConceptScore W2395071949C2778074680 @default.
• W2395071949 hasConceptScore W2395071949C2778716859 @default.
• W2395071949 hasConceptScore W2395071949C2780334268 @default.
• W2395071949 hasConceptScore W2395071949C2780630273 @default.
• W2395071949 hasConceptScore W2395071949C42219234 @default.
• W2395071949 hasConceptScore W2395071949C71924100 @default.
• W2395071949 hasConceptScore W2395071949C78519656 @default.
• W2395071949 hasIssue "8" @default.
• W2395071949 hasLocation W23950719491 @default.
• W2395071949 hasLocation W23950719492 @default.

• next